MMP2 and prostate carcinoma: Hypomethylation of the promoter regions of tumor-promoting genes such as uPA and matrix metalloproteinase-2 (MMP-2) have been associated with tumor growth in prostate cancer PC-3 cell line, which can be reverted by SAMe treatment [212].